Rigel to Participate in Upcoming September Investor Conferences
Rigel Pharmaceuticals (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer, announced its participation in two upcoming investor conferences in September 2024. Dean Schorno, the company's CFO, will represent Rigel at:
1. The 2024 Wells Fargo Healthcare Conference in Boston, MA on September 5th for one-on-one meetings.
2. The H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on September 10th, where he will participate in one-on-one meetings and present a company overview at 11:30 a.m. ET.
A live webcast of the H.C. Wainwright presentation will be available on Rigel's website. Founded in 1996, Rigel is based in South San Francisco, California, and is dedicated to developing novel therapies for patients with hematologic disorders and cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL), una società biotecnologica concentrata sui disturbi ematologici e sul cancro, ha annunciato la sua partecipazione a due imminenti conferenze per investitori a settembre 2024. Dean Schorno, il CFO dell'azienda, rappresenterà Rigel presso:
1. La 2024 Wells Fargo Healthcare Conference a Boston, MA, il 5 settembre per incontri one-to-one.
2. La H.C. Wainwright 26th Annual Global Investment Conference a New York, NY, il 10 settembre, dove parteciperà a incontri individuali e presenterà una panoramica dell'azienda alle 11:30 ET.
Una diretta streaming della presentazione di H.C. Wainwright sarà disponibile sul sito web di Rigel. Fondata nel 1996, Rigel ha sede a South San Francisco, California, ed è dedicata allo sviluppo di terapie innovative per pazienti con disturbi ematologici e cancro.
Rigel Pharmaceuticals (Nasdaq: RIGL), una empresa biotecnológica enfocada en trastornos hematológicos y cáncer, anunció su participación en dos conferencias de inversionistas que se realizarán en septiembre de 2024. Dean Schorno, el CFO de la empresa, representará a Rigel en:
1. La 2024 Wells Fargo Healthcare Conference en Boston, MA el 5 de septiembre para reuniones uno a uno.
2. La H.C. Wainwright 26th Annual Global Investment Conference en Nueva York, NY el 10 de septiembre, donde participará en reuniones individuales y presentará una visión general de la empresa a las 11:30 a.m. ET.
Una transmisión en vivo de la presentación de H.C. Wainwright estará disponible en el sitio web de Rigel. Fundada en 1996, Rigel tiene su sede en South San Francisco, California, y se dedica a desarrollar terapias novedosas para pacientes con trastornos hematológicos y cáncer.
리겔 제약(Rigel Pharmaceuticals, 나스닥: RIGL)은 혈액 장애 및 암에 중점을 둔 생명공학 회사로서 2024년 9월에 예정된 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 회사의 CFO인 딘 숀로(Dan Schorno)가 리겔을 대표할 예정입니다:
1. 2024 웰스파고 헬스케어 컨퍼런스(2024 Wells Fargo Healthcare Conference)가 메사추세츠주 보스턴에서 9월 5일에 1:1 미팅을 위한 회의로 열립니다.
2. 뉴욕주 뉴욕에서 열리는 H.C. 웨인라이트 제26회 글로벌 투자 컨퍼런스에는 9월 10일에 참석하여 1:1 미팅에 참여하고 오전 11시 30분(ET)에 회사 개요를 발표할 예정입니다.
H.C. 웨인라이트 발표의 실시간 웨비나는 리겔의 웹사이트에서 확인할 수 있습니다. 1996년에 설립된 리겔은 캘리포니아 주 사우스 샌프란시스코에 본사를 두고 있으며, 혈액 장애 및 암 환자를 위한 혁신적인 치료제를 개발하는 데 전념하고 있습니다.
Rigel Pharmaceuticals (Nasdaq : RIGL), une entreprise biotechnologique spécialisée dans les troubles hématologiques et le cancer, a annoncé sa participation à deux conférences pour investisseurs prévues en septembre 2024. Dean Schorno, le directeur financier de l'entreprise, représentera Rigel lors de :
1. La 2024 Wells Fargo Healthcare Conference à Boston, MA, le 5 septembre, pour des réunions individuelles.
2. La H.C. Wainwright 26th Annual Global Investment Conference à New York, NY, le 10 septembre, où il participera à des réunions individuelles et présentera un aperçu de l'entreprise à 11h30 (ET).
Une diffusion en direct de la présentation de H.C. Wainwright sera disponible sur le site Web de Rigel. Fondée en 1996, Rigel est basée à South San Francisco, en Californie, et se consacre au développement de thérapies novatrices pour les patients atteints de troubles hématologiques et de cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL), ein biotechnologisches Unternehmen, das sich auf hämatologische Erkrankungen und Krebs spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Dean Schorno, der CFO des Unternehmens, wird Rigel vertreten bei:
1. Der 2024 Wells Fargo Healthcare Conference in Boston, MA am 5. September für Einzelgespräche.
2. Der H.C. Wainwright 26th Annual Global Investment Conference in New York, NY am 10. September, wo er an Einzelgesprächen teilnehmen und um 11:30 Uhr ET einen Unternehmensüberblick präsentieren wird.
Ein Live-Stream der H.C. Wainwright-Präsentation wird auf der Website von Rigel verfügbar sein. Gegründet im Jahr 1996 mit Sitz in South San Francisco, Kalifornien, widmet sich Rigel der Entwicklung neuartiger Therapien für Patienten mit hämatologischen Erkrankungen und Krebs.
- None.
- None.
- 2024 Wells Fargo Healthcare Conference,
Boston, MA
Mr. Schorno will participate in one-on-one meetings on Thursday, September 5th.
- H.C. Wainwright 26th Annual Global Investment Conference,
New York, NY
Mr. Schorno will participate in one-on-one meetings and present a company overview on Tuesday, September 10th at 11:30 a.m. ET.
To access the live webcast or archived recording of the H.C. Wainwright Conference presentation, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-participate-in-upcoming-september-investor-conferences-302233721.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
What investor conferences will Rigel Pharmaceuticals (RIGL) attend in September 2024?
Who will represent Rigel Pharmaceuticals (RIGL) at the September 2024 investor conferences?
When and where will Rigel Pharmaceuticals (RIGL) present at the H.C. Wainwright Conference?
How can investors access Rigel Pharmaceuticals' (RIGL) presentation at the H.C. Wainwright Conference?
What is the main focus of Rigel Pharmaceuticals (RIGL) as a biotechnology company?
